Pricing Log in Create free account

AbCellera Biologics Inc. (ABCL) vs Definium Therapeutics, Inc. (DFTX)

AbCellera Biologics Inc. and Definium Therapeutics, Inc. are both Biotechnology companies. Definium Therapeutics, Inc. is the larger, with a market value of $4.6B against $4.1B — 1.1× the size. Definium Therapeutics, Inc. has the higher net margin (0.00% vs −248.8%) and the higher return on invested capital (0.00% vs −42.5%). Across the 14 metrics below, AbCellera Biologics Inc. leads on 8 and Definium Therapeutics, Inc. on 6.

Valuation

Metric ABCL DFTX Biotechnology median
P/E n/m n/m 8.50
P/S 54.49 n/m 9.71
P/B 4.02 3.87 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 46.00 n/m 9.21
Earnings yield (4.58%) (10.69%) (33.15%)
Free cash flow yield (3.41%) (4.73%) (25.50%)

Profitability

Metric ABCL DFTX Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (340.25%) 0.00% 0.00%
Net margin (248.82%) 0.00% 0.00%
Free cash flow margin (180.84%) 0.00% 0.00%
Return on equity (17.30%) (64.09%) (56.36%)
Return on assets (12.15%) (51.35%) (48.04%)
Return on invested capital (42.52%) 0.00% 0.00%

Growth

Metric ABCL DFTX Biotechnology median
Revenue growth (TTM) 101.29% — 6.02%
EPS growth (last fiscal year) 10.91% (33.77%) 30.26%
Revenue growth, 5-year CAGR (20.27%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABCL DFTX Biotechnology median
Debt to equity 0.00 0.04 0.00
Current ratio 12.77 6.95 4.72
Net debt to EBITDA 2.97 2.21 0.96

Dividend

Metric ABCL DFTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ABCL DFTX Biotechnology median
Market cap 4.11b 4.60b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack